Table 1 Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver
PATIENT 1 | PATIENT 2 | PATIENT 3 | PATIENT 4 | |
|---|---|---|---|---|
Description of Cases | ||||
Age at SCNECP Diagnosis (years) | 74 | 68 | 74 | 76 |
CPAC Gleason Grade | 3 + 4 = 7 | 4 + 5 = 9 | 3 + 4 = 7 | 4 + 5 = 9 |
PSA Level (ng/mL) at CPAC Diagnosis | 5.81 | 50 | 5.6 | 68.9 |
Average Interval Between CPAC and SCNECP (months) | 144 | 12 | 168 | 84 |
Liver Biopsy Site | NOS | Right hepatic lobe | NOS | Right hepatic lobe |
Average PSA Level (ng/mL) at SCNECP Diagnosis (ref: 0–4) | 5.1 | 0.31 | 5.12 | 8.77 |
Average CEA Level (ng/mL) at SCNECP Diagnosis (ref: 0–4.7 ng/mL) | 52.3 | 4.8 | N/A | 28.2 |
Average CA19–9 Level (U/mL) at SCNECP Diagnosis (ref: 0–35 U/mL) | 18 | 1048 | N/A | N/A |
ADT | Yes | Yes | Yes | Yes |
Radiation | Yes | Yes | Yes | Yes |
Chemotherapy | Yes | Yes | No | Yes |
Radical Prostatectomy | Yes | No | Yes | No |
Sites of SCNECP Metastasis | Liver, rectum, various LN | Liver, retroperitoneal LN | Liver, adrenal, retroperitoneal LN, bone | Liver and bone |
Average Interval Between SCNECP and Death (months) | 26 | 2 | 0.75 | 4.5 |
Pathologic Findings | ||||
Synaptophysin | + | + | + | + |
Chromogranin | + | + | + | + |
AE1/AE3 | + | + | + | + |
Ki-67 | > 90% | > 90% | 80–90% | 70–80% |
NKX3.1 | – | – | Focal + | – |
TTF-1 | + | – | – | + |
PSA | N/A | – | N/A | – |
PAP | N/A | – | N/A | + |
ERG | + (weak)* | – | – | – |